Ifosfamide Eg

Ifosfamide, the active ingredient in Ifosfamide Eg, is an alkylating agent presented as an unknown/unknown for intravenous use. It is used in the treatment of various solid tumours and lymphomas, including testicular cancer, soft‑tissue sarcoma, ovarian cancer and central nervous system tumours, in adult patients.

GNH USA supplies Ifosfamide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ifosfamide is an alkylating agent used in the management of several malignant neoplasms.

- Testicular cancer: improves survival by targeting rapidly dividing germ cells. - Soft tissue sarcoma: reduces tumor burden and prolongs progression‑free survival. - Lymphoma: contributes to remission in refractory cases. - Ovarian cancer: enhances response when combined with platinum agents. - CNS tumors: provides cytotoxic effect against malignant brain tumors.

Adverse reactions may occur with ifosfamide therapy.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Fatigue - Myelosuppression (decreased blood cell counts) - Hemorrhagic cystitis - Electrolyte disturbances

Serious or Rare Side Effects: - Nephrotoxicity (kidney damage) - Encephalopathy (central nervous system toxicity) - Severe neutropenia and infection risk - Thrombocytopenia with bleeding tendency - Cardiotoxicity - Secondary malignancies such as leukemia

Before initiating ifosfamide, several safety considerations are recommended.

- Renal function monitoring: assess baseline creatinine and maintain hydration to reduce nephrotoxicity. - Hematologic monitoring: perform regular CBCs to detect myelosuppression. - Mesna co‑administration: use to prevent hemorrhagic cystitis. - Avoid in patients with known hypersensitivity to ifosfamide or its excipients. - Pregnancy and breastfeeding: risk unknown; avoid use unless clearly justified. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ifosfamide may interact with other medicines, requiring caution.

Major Interactions (Avoid): - Concurrent nephrotoxic agents (e.g., cisplatin) increase renal toxicity. - Other alkylating agents heighten myelosuppression risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole) raise plasma levels of ifosfamide.

Moderate Interactions (Monitor Closely): - CYP inducers (e.g., rifampin) may reduce therapeutic effect. - Anticoagulants: increased bleeding risk due to thrombocytopenia. - Radiotherapy: potential for enhanced tissue toxicity when combined.